Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China

Abstract The results of the ETER701 trial showed that benmelstobart and anlotinib plus chemotherapy have potential advantages in the treatment of extensive small cell lung cancer (ES-SCLC). However, it must be noted that the high cost cannot be ignored. This study was designed to assess the cost-eff...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chunyan Yan, Zhengxiong Li, Jiayan Li, Quan Zhao, Wenxiu Cao, Shuqing Li, Ruigang Diao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-03-01
Edice:	Scientific Reports
Témata:	Cost-effectiveness Benmelstobart Anlotinib Extensive-stage small cell lung cancer Partitioned survival model First-line
On-line přístup:	https://doi.org/10.1038/s41598-025-91540-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!